← Back to Patent Explorer
US4920143A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Assignee: BRITISH COLUMBIA A CORP OF VANCOUVER BC CANADA, University of
•
Filing: 1988-07-19
•
Granted: 1990-04-24
•
Expires: 2008-07-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.

Inventors

  • 👤 Julia G. Levy
  • 👤 David Dolphin
  • 👤 Jack K. Chow
  • 👤 Ethan Sternberg

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 16:58
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0485; A61K41/00; A61K41/0057; A61K41/0071; A61K49/00; A61K49/001; A61K49/0013; A61K49/0017; A61K49/0019; A61K49/0021; A61K49/0036; A61K49/005; A61K49/0058; A61K51/08; A61K51/10; A61K51/1093; C; C07; C07D; C07D487/00; C07D487/22; C07D519/00; A61K2121/00

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 131 words
A compound of the formula ##STR7## wherein each R 1 and R 2 is independently selected from the group consisting of carbalkoxy (1-6C), alkyl (1-6C) sulfonyl, aryl sulfonyl, and aryl, and each R 3 is independently CH 2 CH 2 COOR 3' where R 3' is H or alkyl (1-6C); and R 4 is CHCH 2 , CH 2 OR 4' , CH(OR 4' )CH 3 , CH(OR 4' )CH 2 OR 4' , --CH(SR 4' )CH 3 , --CH(NR 4' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR 4' )CH 3 , --CH(OOCR 4' , )CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein R 4' is H, alkyl (1-6C), with the proviso that if R 4 is CHCH 2 , both R 3' , cannot be alkyl.
Claim 2
Dependent Claim 131 words
A compound of the formula ##STR7## wherein each R 1 and R 2 is independently selected from the group consisting of carbalkoxy (1-6C), alkyl (1-6C) sulfonyl, aryl sulfonyl, and aryl, and each R 3 is independently CH 2 CH 2 COOR 3' where R 3' is H or alkyl (1-6C); and R 4 is CHCH 2 , CH 2 OR 4' , CH(OR 4' )CH 3 , CH(OR 4' )CH 2 OR 4' , --CH(SR 4' )CH 3 , --CH(NR 4' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR 4' )CH 3 , --CH(OOCR 4' , )CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein R 4' is H, alkyl (1-6C), with the proviso that if R 4 is CHCH 2 , both R 3' , cannot be alkyl.
Claim 3
Dependent Claim 13 words
The compound of claim 1 wherein R 1 and R 2 are carbalkoxy.
Claim 4
Dependent Claim 15 words
The compound of claim 2 wherein R 1 and R 2 are carbomethoxy or carboethoxy.
Claim 5
Dependent Claim 16 words
The compound of claim 2 which is of formulae mulae 3 or 4 of FIG. 1.
Claim 6
Dependent Claim 20 words
The compound of claim 2 wherein R 4 is selected from --CHCH 2 , --CH(OH)CH 3 and --CH(halo)CH 3 .
Claim 7
Dependent Claim 19 words
The compound of claim 2 which is selected from compounds of the formula ##STR8## wherein R is alkyl (1-6C).
Claim 8
Dependent Claim 10 words
The compound of claim 5 which is of the formula
Claim 9
Dependent Claim 32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.
Claim 10
Dependent Claim 32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 5 in admixture with at least one pharmaceutically acceptable excipient.
Claim 11
Dependent Claim 32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 6 in admixture with at least one pharmaceutically acceptable excipient.
Claim 12
Dependent Claim 32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 7 in admixture with at least one pharmaceutically acceptable excipient.

References Cited (Backward Citations)

US2951800A Cited
US4649151A Cited
US4675338A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-04-23 1993-10-23 1994-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-04-23 1997-10-23 1998-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-04-23 2001-10-23 2002-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag